EP3340990

PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    24.8.2016
  • :
    25.9.2019
  • :
    16763585.3
  • :
    23.8.2036
  • :
    PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER

24.8.2016
25.9.2019
  • :
    Novartis AG
  • :
    Lichtstrasse 35, 4056, Basel, CH
  • :
    CAPONIGRO, Giordano
  • :
    Cambridge, Massachusetts, US
  • :
    HORN-SPIROHN, Thomas
  • :
    Cambridge, Massachusetts, US
  • :
    LEHAR, Joseph
  • :
    Cambridge, Massachusetts, US
  • :
    201562211031 P
  • :
    28.8.2015
  • :
    US
  • :
    IB2016055044
  • :
    24.8.2016
  • :
    A61K 31/517, A61K 31/519, A61P 35/00